Dr Clive has been a consultant medical oncologist in NHS Lothian since 2007. She specialises in the oncological management of colorectal cancer, the management of patients with cancers of unknown primary (CUP) and cancer therapeutics. Her current research interests in CUP include improving pathways to CUP diagnosis, using real world data to support cancer management and optimising diagnosis and management through genomic testing. She is principal investigator for numerous phase II and III clinical trials in CUP and colorectal cancer in NHS Lothian and NHS Fife. She is SACT lead for NHS Lothian and Chair of the Scottish National Cancer Medicines Advisory Group.

Reflecting on the genomics panel’s aims, Sally said: “As cancer diagnosis becomes increasingly complex, molecular cancer subtypes are recognised as not only affecting prognosis but also increasingly influencing treatment options. Early genomic classification of cancers can improve access to treatments that improve outcomes for patients. This is particularly apparent in patients with Cancers of Unknown Primary where the primary cancer type cannot be diagnosed by conventional means, time to treatment is critical, and genomic profiling can provide valuable information to support diagnosis of cancer type as well as identify druggable targets. Easily available access to standardised genomic profiling for patients with CUP would bring Scotland in line with the rest of the world and optimise CUP management to improve information and outcomes for patients.”